Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children18510.24287/1726-1708-2018-17-2-136-143LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫEconomic methods of medical technology assessment in hematologyЭкономические методы оценки эффективности медицинских технологий в гематологииhttps://orcid.org/0000-0003-4727-0131GurkinaM. V.ГуркинаМ.В.
Russian Federation

adviser to General Director

Russia 117997, Moscow, Samory Mashela st., 1

mvgurkina@gmail.comhttps://orcid.org/0000-0003-2756-7325SmetaninaN. S.СметанинаН.С.
Russian Federation
https://orcid.org/0000-0002-1643-5960RumyntsevA. G.РумянцевА.Г.
Russian Federation
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Department of Hematology, Oncology and radiotherapy Russian National Research Medical University named after N.I. PirogovФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России2009201817213614320092018Copyright ©; 1970, «D. Rogachev NMRCPHOI»Copyright ©; 1970, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России1970«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/185

The use of available resources with maximum benefit to the patient is the main goal of healthcare, therefore the economic evaluation of the effectiveness of medical technologies becomes important. In this article all modern methods of pharmacoeconomic analysis are presented in detail on the example of hematological diseases. Particular attention is paid to the characteristics by which healthcare providers can assess the validity of data on the pharmacoeconomic effectiveness of medical technologies.

Использование имеющихся материальных ресурсов с максимальной пользой для пациента - главная задача здравоохранения, поэтому клинико-экономическая оценка эффективности медицинских технологий приобретает важную роль. В настоящей статье подробно, на примере гематологического заболевания, представлены все современные методы фармакоэкономического анализа. Особое внимание уделено характеристикам, по которым организаторы здравоохранения могут оценить валидность данных о фармакоэкономической эффективности медицинских технологий.

economic evaluationpharmacoeconomic analysisdecision-treeMarkov modelsensitivity analysishematologyклинико-экономический анализфармакоэкономический анализдрево решениймодель Марковаанализ чувствительностигематологияAmerican society of hematology: http://www.hematology.org/Clinicians/Drugs/Programs/Saret C., Winn A. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 2015: blood-2014-07-592832.Scalone L., Mantovani L.G., Krol M., Rofail D., Ravera S., Bisconte MG. et al. Costs, quality o flife, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008; 24: 1905-17.СмитМ.Д., БергерМ.Л., ред. Затраты, качество и результаты в здравоохранении: книга терминов ISPOR (Пер. с англ.). - М.: Ньюдиамед, 2009.Хабриев Р.У., Ягудина Р.И., Правдюк Н.Г. Оценка технологий здравоохранения. - М.: Медицинское информационное агентство, 2013.Воробьев П.А., ред. Клинико-эконо-мический анализ. - М.: Ньюдиамед; 2008, 778 с.Ademi Z., Kim H., Zomer E., Reid C.M., Hollingsworth B., Liew D. Overview of pharmacoeconomic modelling methods. BJCP 2013; 75 (4): 944-50.Федеральный закон от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств».Постановление Правительства от 28.08.2014 № 871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи».George B., Harris A., Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19 (11): 1103-9.Delea T.E., Sofrygin O., Thomas S.K., Edelberg J., Baladi J.-F., Phatak P.D., Coates T.D. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia [abstract no. 7637]. ISPOR 11th Annual International Meeting; 2006 May 20-24; Philadelphia (PA).Zhang B., Donga B., Corral M., Sasane M., Miller J.D., Pashos C.L. Pharmacoeconomic considerations in treating iron overload in patients with -thalassaemia, sickle cell disease and myelodysplastic syndromes in the US. Pharmacoeconomics 2011; 29 (6): 461-74.Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107 (9): 3455-62.Kwiatkowski J.L. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program 2011; 2011: 451-8.Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russel L.B. Recom-mendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276 (15): 1253-8.American College of Physicians. Information on cost-effectiveness: an essential product of national comparative effectiveness program. Ann Intern Med 2008; 148; 956-61.Shah S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Annals of pharmacotherapy 2006; 40 (9); 1527-33.Payne K.A., Desrosiers M.P., Caro J.J., Baladi J.F., Lordan N., Prokovsky I., et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007; 47: 1820-9.Ягудина Р.И., Куликов А.Ю., Литвиненко М.М. QALY: история, методология и будущее метода. Фармакоэкономика 2010; 3 (1); 7-11.Kilbridge K.L. Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underserved. Oncology (Williston Park) 2010; 24 (6): 530-6.Drummond M.F., O’Brien B., Stoddart G.L., Torrance G.W., Sculpher M.J. Methods for the economic evaluation of healthcare programs. 2nd edition. New York: Oxford University Press; 1997.Drummond M.F., Jefferson T.O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313 (7052): 275-83.Euro Qol - a new facility for the measurement of health-related quality of life. The Euro Qol Group. Health Policy 1990; 16 (3): 199-208.Brazier J., Roberts J., Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21 (2): 271-92.Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33 (5): 328-36.Feeny D., Furlong W., Torrance G.W., Goldsmith C.H., Zhu Z., DePauw S., et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002; 40 (2): 113-28.Hawthorne G., Richardson J., Day N., Osborne R., McNeil H. Construction and utility scaling of the Assessment of Quality of Life (AQoL) instrument: Centre for Health Program Evaluation, Monash University; 2000. Working paper 101.Kind P., Lafata J.E., Matuszewski K., Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value in Health 2009; 12; 27-30.Leelahavarong P., Chaikledkaew U., Hongeng S., Kasemsup V., Lubell Y., Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients inThailand. BMC Health Services Research 2010; 10: 209.Sullivan S., Mauskopf J., Augustovski F., Jame Caro J., Lee K.M., Minchin M., et al. Budget impact analysis- principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health 2014; 17; 5-14.Torrance G.W., Thomas W.H., Sackett D.L. A utility maximization model for evaluation of healthcareprograms. Health Se rRes 1972; 7; 118-33.Ho W.L., Chung K.P., Yang S.S., Lu M.Y., Jou S.T., Chang H.H., et al. A pharmacoeconomic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia inTaiwan. J Formos Med Assoc 2013; 112 (4): 221-9.McLeod C., Fleeman N., Kirkham J., Bagust A., Boland A., Chu P., et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Techno lAssess 2009; 13 (1): 1-121.Cappelilini M.D., Cohen A., Porter J., Taher A., Viprakasit V. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd edition. Thalassemia International Federation, 2014.Румянцев А.Г., Токарев Ю.Н., Смета-нина Н.С., ред. Гемоглобинопатии и талассемические синдромы. - М: Прак-тическая медицина, 2015; 448 с.Mantovani L.G., Scalone L., Ravera S. Direct and indirect cost of beta thalassemia major: results from the ITHACA Study Blood 2006; 108: 33-43.Tan S., van Gils C.W., Franken M.G., Hakkaart van Roijen L., Uyl-de Groot C.A., et al. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. ValueinHealth 2010; 13: 712-19.Федеральная служба государственной статистики: http://www.gks.ru/Glick H.A., Doshi J.A., Sonnad S.S., Polsky D. Economic evaluation in clinical trials. NewYork: Oxford University Press; 2007.Willan A., Briggs A. Statistical analysis of cost-effectiveness data. West Sussex (UK): John Wiley & Sons; 2006.Bilcke J., Beutels P., Brisson M., Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011; 31 (4): 675-92.Hashmi S., Pandaya C., Khera N., Ger-tz M.A., Dispenzieri A., Hogan W., et al. Cost effectiveness decision tree analysis of early versus late autologous stem cell transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Blood 2012; 120: 602.Sonnenberg F.A., Beck J.R. Markov models in medical decision making:a practical guide. Med Decis Making 1993; 13 (4): 322-38.